The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Open accessAbstract
BACKGROUND: The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant of PCI-related ischemic complications. Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects. METHODS: In a double-blind, placebo-controlled trial, we randomly assigned 11,145 patients who were undergoing either urgent or elective PCI and were receiving guideline-recommended therapy to receive a bolus and infusion of cangrelor or to receive a loading dose of 600 mg or 300 mg of clopidogrel. The primary efficacy end point was a composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours after randomization; the key secondary end point was stent thrombosis at 48 hours. The primary safety end point was severe bleeding at 48 hours. RESULTS: The rate of the primary efficacy end point was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (adjusted odds ratio with cangrelor, 0.78; 95% confidence interval [CI], 0.66 to 0.93; P=0.005). The rate of the primary safety end point was 0.16% in the cangrelor group and 0.11% in the clopidogrel group (odds ratio, 1.50; 95% CI, 0.53 to 4.22; P=0.44). Stent thrombosis developed in 0.8% of the patients in the cangrelor group and in 1.4% in the clopidogrel group (odds ratio, 0.62; 95% CI, 0.43 to 0.90; P=0.01). The rates of adverse events related to the study treatment were low in both groups, though transient dyspnea occurred significantly more frequently with cangrelor than with clopidogrel (1.2% vs. 0.3%). The benefit from cangrelor with respect to the primary end point was consistent across multiple prespecified subgroups. CONCLUSIONS: Cangrelor significantly reduced the rate of ischemic events, including stent thrombosis, during PCI, with no significant increase in severe bleeding. (Funded by the Medicines Company; CHAMPION PHOENIX ClinicalTrials.gov number, NCT01156571.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citationSteinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease
De Bruyne, B., Pijls, N. H. J., Kalesan, B., Barbato, E., Tonino, P. A. L., Piroth, Z., Jagic, N., Möbius-Winkler, S., Rioufol, G., Witt, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205361 · Cited by 2,772
Price, M. J. (2011) · JAMA · doi:10.1001/jama.2011.290 · Cited by 1,308
Self-citationMehta, S. R., Cannon, C. P., Fox, K. A. A., Wallentin, L., Boden, W. E., Spacek, R., Widimsky, P., McCullough, P. A., Hunt, D., Braunwald, E., et al. (2005) · JAMA · doi:10.1001/jama.293.23.2908 · Cited by 827
Mehta, S. R., Tanguay, J.-F., Eikelboom, J. W., Jolly, S. S., Joyner, C. D., Granger, C. B., Faxon, D. P., Rupprecht, H.-J., Budaj, A., Avezum, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61088-4 · Cited by 825
Self-citationDose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909475 · Cited by 768
Intravenous Platelet Blockade with Cangrelor during PCI
Bhatt, D. L., Lincoff, A. M., Gibson, C. M., Stone, G. W., McNulty, S., Montalescot, G., Kleiman, N. S., Goodman, S. G., White, H. D., Mahaffey, K. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908629 · Cited by 648
Self-citationPlatelet Inhibition with Cangrelor in Patients Undergoing PCI
Harrington, R. A., Stone, G. W., McNulty, S., White, H. D., Lincoff, A. M., Gibson, C. M., Pollack, C. V., Montalescot, G., Mahaffey, K. W., Kleiman, N. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908628 · Cited by 625
Self-citationBhatt, D. L., Roe, M. T., Peterson, E. D., Li, Y., Chen, A. Y., Harrington, R. A., Greenbaum, A. B., Berger, P. B., Cannon, C. P., Cohen, D. J., et al. (2004) · JAMA · doi:10.1001/jama.292.17.2096 · Cited by 568
Self-citationBenefit of Early Invasive Therapy in Acute Coronary Syndromes
Bavry, A. A., Kumbhani, D. J., Rassi, A. N., Bhatt, D. L., & Askari, A. T. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.050 · Cited by 556
Self-citationAngiolillo, D. J., Firstenberg, M. S., Price, M. J., Tummala, P. E., Hutyra, M., Welsby, I. J., Voeltz, M. D., Chandna, H., Ramaiah, C., Brtko, M., et al. (2012) · JAMA · doi:10.1001/jama.2011.2002 · Cited by 481
Self-citationAlexopoulos, D., Xanthopoulou, I., Gkizas, V., Kassimis, G., Theodoropoulos, K. C., Makris, G., Koutsogiannis, N., Damelou, A., Tsigkas, G., Davlouros, P., et al. (2012) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.112.972323 · Cited by 396
Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
Bhatt, D. L. (2000) · JAMA · doi:10.1001/jama.284.12.1549 · Cited by 269
Self-citationBonello, L., Pansieri, M., Mancini, J., Bonello, R., Maillard, L., Barnay, P., Rossi, P., Ait-Mokhtar, O., Jouve, B., Collet, F., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.04.017 · Cited by 209
Bellemain-Appaix, A., O’Connor, S. A., Silvain, J., Cucherat, M., Beygui, F., Barthélémy, O., Collet, J.-P., Jacq, L., Bernasconi, F., Montalescot, G., et al. (2012) · JAMA · doi:10.1001/jama.2012.50788 · Cited by 204
Intensifying Platelet Inhibition — Navigating between Scylla and Charybdis
Bhatt, D. L. (2007) · New England Journal of Medicine · doi:10.1056/nejme0706859 · Cited by 179
Self-citationHeestermans, A. A. C. M., van Werkum, J. W., Taubert, D., Seesing, T. H., von Beckerath, N., Hackeng, C. M., Schömig, E., Verheugt, F. W. A., & ten Berg, J. M. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.01.021 · Cited by 172
Angiolillo, D. J., Schneider, D. J., Bhatt, D. L., French, W. J., Price, M. J., Saucedo, J. F., Shaburishvili, T., Huber, K., Prats, J., Liu, T., et al. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0737-3 · Cited by 159
Self-citationWidimský, P., Motovska, Z. J., Simek, S., Kala, P., Pudil, R., Holm, F., Petr, R., Bilkova, D., Skalická, H., Kuchynka, P., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn169 · Cited by 147
Self-citationSosnowski, C. (2008) · PubMed · Cited by 143
Optimizing Trial Design: Sequential, Adaptive, and Enrichment Strategies
Mehta, C. R., Gao, P., Bhatt, D. L., Harrington, R. A., Skerjanec, S., & Ware, J. H. (2009) · Circulation · doi:10.1161/circulationaha.108.809707 · Cited by 113
Self-citationThe evolution of antiplatelet therapy in cardiovascular disease
Yousuf, O. K., & Bhatt, D. L. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.96 · Cited by 105
Self-citationWhite, H. D., Chew, D. P., Dauerman, H. L., Mahaffey, K. W., Gibson, C. M., Stone, G. W., Gruberg, L., Harrington, R. A., & Bhatt, D. L. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.11.001 · Cited by 104
Self-citationLeonardi, S., Mahaffey, K. W., White, H. D., Gibson, C. M., Stone, G. W., Steg, P. G., Hamm, C. W., Price, M. J., Todd, M., Dietrich, M., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.02.018 · Cited by 79
Self-citationThe State of Periprocedural Antiplatelet Therapy After Recent Trials
Desai, N. R., & Bhatt, D. L. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.04.008 · Cited by 54
Self-citationIntra-Procedural Stent Thrombosis
Brener, S. J., Cristea, E., Kirtane, A. J., McEntegart, M. B., Xu, K., Mehran, R., & Stone, G. W. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.08.018 · Cited by 50
Self-citationBhatt, D. L. (2005) · JAMA · doi:10.1001/jama.293.23.2935 · Cited by 31
Self-citation
Cited by
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citation2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Metadata
- Authors
- Bhatt, D. L., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Steg, P. G., Hamm, C. W., Price, M. J., Leonardi, S., Gallup, D., Bramucci, E., Radke, P. W., Widimský, P., Tousek, F., Tauth, J., Spriggs, D., McLaurin, B. T., Angiolillo, D. J., Généreux, P., Liu, T., Prats, J., Todd, M., Skerjanec, S., White, H. D., & Harrington, R. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-04-04
- Volume
- 368
- Issue
- 14
- Pages
- 1303-1313
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2150655309
- Cited by
- 840
- References
- 29
- FWCI
- 69.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.